

184-Pos**Selectivity of Binding To Estrogen Receptors Alpha and Beta As Determined by Fluorescence Polarization**

Catherine T. Knuff, Hannah M. Varner, Patricia B. O'Hara.

Amherst College, Amherst, MA, USA.

Estrogen's role in cell growth and proliferation has long been appreciated both in the normal development of secondary sexual characteristics and in diseased states in cancers of the breast, ovaries and uterus. We are beginning to appreciate estrogen's expanded role in maintaining such diverse functions as the skin's elasticity, the health of the central nervous system, bone density and cardiac health. Estrogen plays out its roles in varied tissues by binding to two major ligand activated nuclear receptors, estrogen receptor alpha (ER- α) and estrogen receptor beta (ER- β). The interrelationship of the two receptors plays a role in the responsiveness of certain breast cancers to drug treatment. Though the ligand binding sites of the two receptors differ by only two amino acids, the overall degree of homology between ER- α and ER- β is low. The body uses the receptor selectivity to its advantage by dispersing the receptors in varying ratios to different tissues. Of these actions ER- α is thought to be responsible for the majority with ER- β playing a minor role in all and having more significance in the cardiovascular and skeletal systems. Small molecules have been identified which bind to one or the other receptors with differing binding affinities. These selective estrogen receptor modulators (SERMs) hold the potential to be pharmacologically effective in treating diseases specific to one type of estrogen receptor while not affecting the other. For example, ER- α and ER- β are both present in breast tissue, and the ratio of beta to alpha is being examined as one indicator in determining the likelihood of successful treatment of breast cancer by certain drugs. Here we use changes in the fluorescence polarization to calculate binding affinities for each of several small molecules to ER- α and ER- β .

185-Pos**Ion Channel Blockade of NMDA Receptors By Argiotoxins: Identification of Structural Determinants For Subtype Selectivity**Anders S. Kristensen¹, Simon Lucas¹, Claudius Wenzler¹,Dennis B. Tikhonov², Kristian Strömgaard¹.¹University of Copenhagen, Copenhagen, Denmark, ²Russian Academy of Sciences, St. Petersburg, Russian Federation.

The NMDA family of ionotropic glutamate receptors are ligand-gated ion channels that mediate the majority excitatory synaptic transmission in the brain. Dysfunction of NMDA receptor signalling is involved in a range of neurological and psychiatric diseases for which NMDA receptors are considered important drug targets. NMDA receptors are tetrameric assemblies comprised of two glycine-binding GluN1 subunits and two glutamate-binding GluN2 subunits. Four different GluN2 subunits (GluN2A-D) exist with distinct expression and functional profiles. Identification of subunit-selective NMDA receptor agonists, antagonists, or modulators could prove to be both valuable pharmacological tools as well as potential new therapeutic agents.

Polyamine toxins are a group of small molecules found in spiders and wasps that are open-channel blockers of NMDA receptors. Polyamine toxins have found valuable use as pharmacological tools based on their high affinity and selectivity, but have not yet been explored as templates for the development of NMDA receptor drugs. Argiotoxin-636 (ArgTX-636) is a polyamine toxin isolated from the venom of the orb weaver spider *Argiope lobata*. ArgTX-636 is among the most potent inhibitors of NMDA receptors and blocks these in a use- and voltage-dependent manner, presumably by binding to the ion channel region. We have recently shown that modifications within the polyamine tail of ArgTX-636 can control subtype selectivity. In this study, we explore the rational design of ArgTX-636 analogs to produce NMDA receptor inhibitors with marked improvement in subtype selectivity. Systematic variation of the polyamine tail lead to identification of ArgTX analogs with pronounced subtype selectivity, such as 100-fold differential potency between GluN2A, GluN2B, or GluN2C versus GluN2D containing receptors. To study the structural basis for NMDA subtype selectivity, compounds were docked into models of the NMDA receptor ion channels.

186-Pos**A Survey for Small Multidrug Resistance Protein Multimerization in the Presence of Ligand Using Sds-Page Analysis**

Denice C. Bay, Raymond J. Turner.

University of Calgary, Calgary, AB, Canada.

EmrE and SugE are members of the small multidrug resistance protein family that can efflux quaternary cation compounds (QCC) via proton motive force within the *Escherichia coli* plasma membrane. Members of this integral membrane protein family are characterized by their short (~100-140 amino acids) four transmembrane (TM) alpha-helix conformation and highly conserved

glutamate residue within the active site. EmrE protein can confer broad multidrug resistance to the host strain unlike SugE protein, which demonstrates limited multidrug resistance. The exact multimeric state or states of both proteins during transport and ligand binding is not well understood and often yield conflicting results that are specific to the conditions of study. To explore SMR multimerization as influenced by QCC ligands, organic solvent extracted EmrE and SugE protein from *E. coli* membranes were characterized in the detergents, sodium dodecyl sulfate (SDS) and dodecyl maltoside (DDM) at varying protein concentrations. SMR proteins solubilized in both detergents demonstrated a predominately monomeric state but upon increasing particular QCC ligand concentrations resulted in multimer formation or enhancement using SDS-tricine polyacrylamide gel electrophoresis (PAGE). The results from this PAGE based assay demonstrate that: i) SMR multimers are induced by particular ligands that may relate to ligand shape and ii) only EmrE multimerization is induced by particular ligands, whereas SugE appears to be insensitive to drug enhanced oligomerization. Therefore, SMR multimer variability may be dependent upon the nature of the transported substrate and SMR subclass; only EmrE can alter its subunit composition in response to particular QCC substrates. This PAGE based assay provides the framework to explore the influence of diverse QCC substrates for its effects on SMR multimerization.

187-Pos**Towards Identifying the Structural Basis For Inhibition By a Newly Discovered Class of CLC Chloride-Channel Inhibitors**

Andrew E. Howery, Jonas Almqvist, Justin Du Bois, Merritt Maduke.

Stanford University, Stanford, CA, USA.

CLC chloride channels and transporters play diverse physiological roles. Small-molecule inhibitors of the CLCs would be powerful tools to understand and potentially treat a variety of CLC-related human diseases. In addition to their potential therapeutic benefits, inhibitors can be used to trap channels or transporters in particular conformational states, potentially advancing our understanding of the structural basis for CLC activity. Despite their usefulness, specific small molecule inhibitors for CLC proteins are scarce. To address this shortfall, we have embarked on a search for novel inhibitors of the CLC proteins. We have discovered a panel of small molecules active against both the human CLC-K and the prokaryotic CLC-ec1 homologs. Because CLC-ec1 is amenable to structural studies by X-ray crystallography, co-crystallization experiments with these novel inhibitors are in progress. As an alternative method to identifying the inhibitor-binding site, we have synthesized photo-reactive diazirine derivatives of the inhibitors and shown that these photo-affinity reagents specifically inhibit CLC-ec1. Experiments to identify the binding site using protease digestion coupled with mass spectrometry are currently underway. Once located, protein/inhibitor interactions gleaned from the labeling of CLC-ec1 could allow us to rationally design more potent inhibitors of mammalian transporters and channels.

188-Pos**Structural Basis For the Allosteric Mechanism of Serine Protease Inhibition By An Antibody**

Rajkumar Ganesan.

Genentech Inc, South San Francisco, CA, USA.

The widespread use of antibody therapeutics and the emergence of proteases as compelling disease targets contrast sharply with our poor understanding of how antibodies achieve protease inhibition. Recent structural studies have outlined the mechanism of serine protease inhibition by active site-directed antibodies. However, the molecular basis of allosteric inhibition by antibodies has been elusive. The present study, with three crystal structures and a comprehensive kinetic analysis, now provides a detailed view of how an allosteric antibody inhibits protease activity. We determined the structure (2.35 Å resolution) of the trypsin-like serine protease hepatocyte growth factor activator (HGFA) in complex with the allosteric antibody Ab40, a competitive inhibitor of HGFA catalytic activity. The antibody binds at the periphery of the substrate binding cleft and imposes a conformational change on the entire 99-loop (chymotrypsinogen numbering). Remarkably, a single residue deletion (Trp96H) of Ab40 abolished inhibition of HGFA activity commensurate with the reversal of the 99-loop conformation to its 'competent' state as evidenced from the structure of HGFA/Fab40.ΔTrp96H resolved at 2.9 Å. In order to understand the precise mechanism by which Ab40 interferes with the proteolytic activity of HGFA, we determined the structure of HGFA/Fab40.ΔTrp96H in complex with substrate-mimicking peptidic inhibitor (Ac-KQLR-chloromethylketone) at 2.7 Å. Comparison of these three structures led us to propose a model wherein the binding of Ab40 to HGFA and the concomitant change in the conformation of the 99-loop may result in the partial collapse of substrate binding subsite S2 and the reorganization of subsite S4, leading to the inhibition of HGFA activity.

by Ab40. Thus our results define a novel 'allosteric switch' mechanism as the basis of protease inhibition by an allosteric antibody.

189-Pos

Allosteric Mechanism in Neurophysin

Hunjoong Lee, Mandar Naik, Clay Bracken, Esther Breslow.

Weill Medical College of Cornell University, New York, NY, USA.

Neurophysins are small two-domain proteins that exhibit ligand-facilitated dimerization and its reciprocal-stronger binding by dimer than by monomer. We have previously reported evidence of conformational differences between unliganded monomer and dimer, but had not established their identity, their origin, or how they affect binding affinity.

In the present study we have determined the relative structures of a neurophysin monomer and its dimer by NMR spectroscopy. The structures show that a number of neurophysin residues that interact with the essential tyrosine of the ligand peptide move from locations in the unliganded monomer that are unfavorable for binding to positions in the unliganded dimer that more closely resemble those of the liganded state, thereby contributing to the stronger binding by dimer. We have also identified the origin of the dimerization-induced conformational change; i.e., the same residues that form the principal inter-domain bonds in the monomer via side-chain interactions form the principal inter-subunit bonds in the dimer via backbone hydrogen bonding. Steric crowding upon dimerization leads to a modification of inter-domain interactions, a resultant change in the relative orientation of the two domains and associated changes in intra-domain interactions. The principal residues responsible for these interactions are the Cys residues of the 28-34 disulfide bridge (amino domain) and 74-79 disulfide bridge (carboxyl domain). Strong inter-domain van der Waals interactions between sulfur atoms appear to play important roles in determining the relative domain orientation.

(Supported by grant GM-17528 from NIH).

190-Pos

Lactose Binding To Galectin-1 Occurs With Negative Cooperativity and Attenuates Internal Motions Throughout the Protein

Irina V. Nesmelova¹, Elena Ermakova², Vladimir A. Daragan³, Mabel Pang⁴, Linda G. Baum⁴, Kevin H. Mayo³.

¹UNCC, Charlotte, NC, USA, ²Kazan Institute of Biochemistry & Biophysics, Kazan, Russian Federation, ³University of Minnesota, Minneapolis, MN, USA, ⁴University of California, Los Angeles, CA, USA. Galectins are a sub-family of lectins with a conserved carbohydrate recognition domain (CRD) that interacts with beta-galactosides. By binding cell surface glycoconjugates, galectin-1 is involved in cell adhesion and migration processes and is an important regulator of tumor angiogenesis. Here, we used heteronuclear NMR spectroscopy and molecular modeling to investigate lactose binding to galectin-1 and to derive solution NMR structures of galectin-1 in the lactose bound and unbound states. Structure analysis shows that the beta-strands and loops around the lactose binding site which are more open and dynamic in the unbound state, fold in around the bound lactose molecule dampening internal motions at that site. Analysis of titration binding data reveal that lactose binds the two CRDs of the galectin-1 dimer with negative cooperativity. Molecular dynamics simulations provide insight into structural dynamics of the half-loaded lactose state and, together with NMR data, suggest that lactose binding at one site transmits a signal through the beta-sandwich and loops to the second binding site. Overall, our results provide new insight into galectin-1 structure-function relationships and to protein-carbohydrate interactions in general.

191-Pos

Conformational Plasticity in IL-2 Is Captured Via in Silico Fragment-Based Drug Design Using SILCS Fragmaps

Olgun Guvench.

University of New England, Portland, ME, USA.

The IL-2 protein is an experimentally well-characterized example of conformational plasticity in a protein-protein binding interface. Whereas the original crystal structure of the IL-2 protein lacked a particular binding pocket at the interface, subsequent structures of the protein complexed with small-molecule inhibitors have shown the creation of a hydrophobic pocket in order to accommodate inhibitor binding poses. A new in silico fragment-based drug design methodology (SILCS FragMaps) was applied to the original IL-2 crystal structure and has been found to recapitulate this pocket observed in the complexes. Furthermore, the pocket is seen to have an affinity for hydrophobic fragments, consistent with experimental inhibitor binding poses. As the SILCS FragMaps methodology is based on explicit-water all-atom molecular dynamics simulations, the methodology is able to capture both the conformational plasticity in the IL-2 surface required for pocket formation as well as the selective partitioning of small hydrophobic fragments into the pocket from bulk solution.

192-Pos

Different Binding Modes of Compounds Affecting CETP Activity: Dalcetrapib and Torcetrapib

Christine Magg, Cyrille Maugeais, Gregor Dernick, Walter Huber, Elisabeth von der Mark, Georg Schmid, Ralf Thoma, Eric J. Niesor. F. Hoffmann - La Roche Ltd., Basel, Switzerland.

Cholesteryl ester transfer protein (CETP) is a hydrophobic glycoprotein in plasma and facilitates the exchange of neutral lipids between various lipoproteins resulting in a net transport of cholesteryl ester from HDL to LDL. Decrease in CETP activity leads to an increase of HDL cholesterol which potentially reduces cardiovascular risk.

Human recombinant CETP (rhCETP) was purified to homogeneity by hydrophobic interaction chromatography and size exclusion chromatography (SEC). The protein showed an extraordinarily high thermodynamic stability against thermal as well as denaturant-induced unfolding.

The effects of CETP on lipoprotein profiles were characterized after *in-vitro* incubation of plasma with rhCETP followed by SEC and reverse phase protein arrays. Monitoring the distribution of apolipoproteins and the cholesterol profiles confirmed the transfer of cholesteryl ester from HDL to LDL induced by CETP. In the presence of the potent CETP inhibitor torcetrapib (1 μ M) added CETP is bound to lipoproteins while free CETP can still be detected in presence of dalcetrapib (3 μ M), a compound from a different chemical class.

¹⁴C-torcetrapib and ¹⁴C-dalcetrapib were bound to CETP immobilized on sepharose and incubated with excess of unlabelled compounds. ¹⁴C-dalcetrapib bound as Dalcetrapib-thiol could only be displaced in the presence of reducing agent by an excess of unlabeled dalcetrapib but not by torcetrapib. Dalcetrapib did not compete for binding of ¹⁴C-torcetrapib.

Interaction studies with Surface Plasmon Resonance confirmed reversible covalent binding of dalcetrapib-thiol and different binding sites for dalcetrapib and torcetrapib. In agreement with literature cysteine 13 of CETP was identified as attachment point of dalcetrapib-thiol. All data suggested that torcetrapib and dalcetrapib bind to different sites on CETP which may be related to differences observed in their pharmacological profiles.

193-Pos

Cholesteryl Ester Transfer Protein Penetrates Lipoproteins For Cholesteryl Ester Transfer

Gang Ren¹, Shengli Zhang², Giorgio Cavigiolio³, Dongsheng Lei², Michael Oda³, Karl H. Weisgraber⁴, Kerry-Anne Rye⁵, Henry J. Pownall⁶, Xiang Qiu⁷.

¹University of California, San Francisco, San Francisco, CA, USA, ²Xi'an Jiaotong University, Xi'an, China, ³Children's Hospital Oakland Research Institute, Oakland, CA, USA, ⁴Gladstone Institute of Neurological Disease, San Francisco, CA, USA, ⁵Heart Research Institute, Newown, Australia, ⁶Baylor College of Medicine, Houston, TX, USA, ⁷Pfizer Global Research and Development, Groton, CT, USA.

Human cholesteryl ester transfer protein (CETP), a hydrophobic glycoprotein (476 amino acids, ~74 kDa), mediates the transfer of cholesteryl ester (CE) from high-density lipoproteins (HDL) to apo-B containing lipoproteins (low-density lipoproteins - LDL; very low density lipoproteins - VLDL). The crystal structure of CETP reveals a banana-shaped protein consisting of N- and C-terminal β -barrel domains, a central β -sheet, and a ~60-Å-long hydrophobic cavity. Since CETP deficiency is associated with elevated 'good-cholesterol' (HDL-associated) levels via delayed catabolism, as a result, CETP has become a high interest pharmacological drug target.

Here, we investigated the mechanism of CETP-mediated neutral lipid transfer by electron microscopy (EM), image-processing, and molecular dynamic simulations (MDS). We discovered that: 1) CETP bridges HDL and LDL/VLDL to form a ternary complex; 2) the CETP C-terminal beta-barrel domain penetrates partially into the LDL/VLDL surface; 3) the N-terminal beta-barrel domain penetrates through the HDL surface and interacts with the CE core; and 4) MDS analysis suggested that the penetrating regions of CETP are highly mobile and form pores that connect to cavities running through the central axis of the CETP molecule to generate a tunnel. The tunnel was mainly hydrophobic and connected the distal ends through its central cavities. Thus, we proposed CETP resembles a Chinese finger trap, in which both beta-barrel domains penetrate the lipoprotein surface, resulting in pressure from both ends. The pressure may result in the anti-twisting of the two domains, leading to opening of the tunnel for CE transfer between HDL and LDL. The distal end of N-terminal beta-barrel domain could be particularly important for the design of pharmacological inhibitors, as blockage of the N-terminal beta-barrel domain would prevent CE transfer with a low probability of off target effects on normal HDL metabolism.